V. Diéras

498 total citations
25 papers, 321 citations indexed

About

V. Diéras is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, V. Diéras has authored 25 papers receiving a total of 321 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 7 papers in Cancer Research. Recurrent topics in V. Diéras's work include Cancer Treatment and Pharmacology (12 papers), Breast Cancer Treatment Studies (5 papers) and Advanced Breast Cancer Therapies (4 papers). V. Diéras is often cited by papers focused on Cancer Treatment and Pharmacology (12 papers), Breast Cancer Treatment Studies (5 papers) and Advanced Breast Cancer Therapies (4 papers). V. Diéras collaborates with scholars based in France, United States and Italy. V. Diéras's co-authors include Vicente Valero, Xueying Zhou, Robin Zoň, David Miles, Javier Cortés, J. O’Shaughnessy, Robert J. Gray, S. Phan, Edith A. Perez and C.H. Barrios and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

V. Diéras

25 papers receiving 311 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
V. Diéras France 8 261 84 65 53 38 25 321
G. Atalay Belgium 7 182 0.7× 82 1.0× 72 1.1× 63 1.2× 50 1.3× 12 317
J-M Ferrero France 10 215 0.8× 74 0.9× 135 2.1× 75 1.4× 37 1.0× 41 319
Özge Gümüşay Türkiye 11 164 0.6× 78 0.9× 124 1.9× 100 1.9× 30 0.8× 42 350
Zora Baretta Italy 9 155 0.6× 118 1.4× 73 1.1× 88 1.7× 65 1.7× 14 337
Lydia Usha United States 9 150 0.6× 82 1.0× 68 1.0× 105 2.0× 18 0.5× 39 296
Carmine Valenza Italy 10 185 0.7× 87 1.0× 86 1.3× 76 1.4× 65 1.7× 47 311
YounJeong Choi United States 11 206 0.8× 51 0.6× 106 1.6× 135 2.5× 75 2.0× 17 369
Maria Elena Jacomuzzi Italy 9 203 0.8× 107 1.3× 38 0.6× 53 1.0× 72 1.9× 17 360
Mariangela Zanghì Italy 7 234 0.9× 79 0.9× 211 3.2× 144 2.7× 40 1.1× 12 414
Ettie Piura Israel 9 181 0.7× 61 0.7× 98 1.5× 202 3.8× 50 1.3× 13 383

Countries citing papers authored by V. Diéras

Since Specialization
Citations

This map shows the geographic impact of V. Diéras's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by V. Diéras with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites V. Diéras more than expected).

Fields of papers citing papers by V. Diéras

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by V. Diéras. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by V. Diéras. The network helps show where V. Diéras may publish in the future.

Co-authorship network of co-authors of V. Diéras

This figure shows the co-authorship network connecting the top 25 collaborators of V. Diéras. A scholar is included among the top collaborators of V. Diéras based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with V. Diéras. V. Diéras is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rugo, H. S., Sherene Loi, Sylvia Adams, et al.. (2019). Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130. Annals of Oncology. 30. v858–v859. 84 indexed citations
2.
3.
Shapiro, Geoffrey I., Mark R. Middleton, Howard A. Burris, et al.. (2013). Pharmacokinetics of orally administered rucaparib in patients with advanced solid tumors.. Molecular Cancer Therapeutics. 12. 3 indexed citations
4.
Campone, M., Christelle Lévy, Mónica Arnedos, et al.. (2013). Abstract S6-07: Genomic characterisation of metastatic samples from breast cancer patients using next generation sequencing. Cancer Research. 73(24_Supplement). S6–7. 2 indexed citations
5.
Bahleda, Rastilav, Lisa Zimmer, Maria Martinez‐García, & V. Diéras. (2012). 243 Phase 1 (Ph1) Clinical and Pharmacodynamic (PD) Study of a Pure MEK Inhibitor (MEKi), RO4987655, in RAS-BRAF Mutant Patient Populations with Advanced or Metastatic Solid Tumors. European Journal of Cancer. 48. 75–75. 1 indexed citations
6.
Tresca, Patricia, Diégo Tosi, Leni van Doorn, et al.. (2010). Phase I and pharmacologic study of the vascular disrupting agent ombrabulin (Ob) combined with docetaxel (D) in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 28(15_suppl). 3023–3023. 5 indexed citations
7.
Diéras, V., Nadia Harbeck, Kathy S. Albain, et al.. (2010). Abstract P3-14-01: A Phase Ib/II Trial of Trastuzumab-DM1 with Pertuzumab for Patients with HER2-Positive, Locally Advanced or Metastatic Breast Cancer: Interim Efficacy and Safety Results. Cancer Research. 70(24_Supplement). P3–14. 34 indexed citations
8.
O’Shaughnessy, J., David Miles, Robert J. Gray, et al.. (2010). A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC).. Journal of Clinical Oncology. 28(15_suppl). 1005–1005. 83 indexed citations
9.
Némati, Fariba, V. Diéras, Ludmilla de Plater, et al.. (2010). 148 In vivo preclinical evaluation of the topoisomerase I inhibitor camptothecin in human triple negative breast cancer xenografts. European Journal of Cancer Supplements. 8(5). 39–39. 1 indexed citations
10.
Gautier, H, et al.. (2009). Meningeal carcinomatosis in patients with breast cancer: clinical features and prognostic factors in 91 patients from a single institution.. Cancer Research. 69(2_Supplement). 1090–1090. 1 indexed citations
11.
Diéras, V., Patrice Viens, Corinne Veyret, et al.. (2008). Larotaxel (L) in combination with trastuzumab in patients with HER2 + metastatic breast cancer (MBC): Interim analysis of an open phase II label study. Journal of Clinical Oncology. 26(15_suppl). 1070–1070. 9 indexed citations
12.
Mathiot, Claire, J.M. Extra, Patricia Tresca, et al.. (2006). Circulating tumor cells (CTCs) detection in a randomized phase II trial of neoadjuvant chemotherapy for large operable and locally advanced breast cancer (REMAGUS 02): Preliminary results. Journal of Clinical Oncology. 24(18_suppl). 10637–10637. 2 indexed citations
13.
Diéras, V., Vicente Valero, Steven Limentani, et al.. (2005). Multicenter, non-randomized phase II study with RPR109881 in taxane-exposed metastatic breast cancer (MBC) patients (pts): Final results. Journal of Clinical Oncology. 23(16_suppl). 565–565. 13 indexed citations
14.
Alexandre, J M, V. Diéras, Sophie Grabar, et al.. (2005). Prospective study of predictive factors of docetaxel (DCX)-induced febrile neutropenia (FN): Relevance of in vivo cytochrome 3A (CYP3A) phenotyping. Journal of Clinical Oncology. 23(16_suppl). 2046–2046. 1 indexed citations
15.
Delbaldo, Catherine, Jean‐Yves Pierga, V. Diéras, et al.. (2003). 552 Evaluation of the pharmacokinetic (PK) interactions between cetuximab and irinotecan in patients with epidermal growth factor receptor (EGFR)-expressing advanced solid tumors. Results of a phase I study. European Journal of Cancer Supplements. 1(5). S167–S167. 6 indexed citations
16.
Valero, Vicente, et al.. (2001). Doxorubicin and taxane combination regimens for metastatic breast cancer: Focus on cardiac effects. Seminars in Oncology. 28(4 Suppl 12). 15–23. 22 indexed citations
17.
18.
Guastalla, Jean‐Paul, Éric Pujade-Lauraine, B. Weber, et al.. (1998). Efficacy and safety of the paclitaxel and carboplatin combination in patients with previously treated advanced ovarian carcinoma. Annals of Oncology. 9(1). 37–43. 35 indexed citations
19.
Pujade-Lauraine, Éric, J P Guastalla, B. Weber, et al.. (1997). Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.. PubMed. 24(5 Suppl 15). S15–30. 8 indexed citations
20.
Chevallier, B, C. Lhommé, V. Diéras, et al.. (1995). 1178 A phase II study of CPT 11 (irinotecan) in chemotherapy naive patients with advanced cancer of the cervix uteri (C.C.U.). European Journal of Cancer. 31. S246–S246. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by G. Atalay Breakdown of academic impact, for papers by J-M Ferrero Breakdown of academic impact, for papers by Özge Gümüşay Breakdown of academic impact, for papers by Zora Baretta Breakdown of academic impact, for papers by Lydia Usha Breakdown of academic impact, for papers by Carmine Valenza Breakdown of academic impact, for papers by YounJeong Choi Breakdown of academic impact, for papers by Maria Elena Jacomuzzi Breakdown of academic impact, for papers by Mariangela Zanghì Breakdown of academic impact, for papers by Ettie Piura
Rankless by CCL
2026